Therapeutics and Diagnostics for Women's Disorders
BCC Research
March 1, 2009 195 Pages - SKU: WA2207852
|
|
This Report:
- Covers a wide variety of products and disorders that predominantly affect women including autoimmune diseases, women’s cancer, gynecological infections and diseases, reproductive-related therapies and diagnostics, rheumatoid arthritis and osteoporosis
- Includes U.S. market forecasts for therapeutics and diagnostics for women’s disorders through 2014
- Provides detailed information based on product categories and their use
- Discusses new therapeutics and diagnostics that have emerged and have a significant impact on women’s health
- Profiles leading companies.
|
- CHAPTER ONE: INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE OF REPORT
- METHODOLOGY
- RELATED BCC STUDIES
- ANALYSTS CREDENTIALS
- BCC RESEARCH ONLINE SERVICES
- DISCLAIMER
- CHAPTER TWO: SUMMARY
- SUMMARY TABLE U.S. MARKET FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, THROUGH 2013 ($ MILLIONS)
- SUMMARY FIGURE U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, 2006-2013 ($ MILLIONS)
- CHAPTER THREE: INDUSTRY OVERVIEW
- DEFINITION OF WOMEN’S DISORDERS
- IMPORTANCE OF THE INDUSTRY AND DEMOGRAPHICS
- TABLE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)
- FIGURE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)
- TABLE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
- FIGURE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
- TABLE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
- FIGURE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
- HISTORY OF THE INDUSTRY AND RESPONSE TO WOMEN’S HEALTHCARE NEEDS
- REGULATORY ENVIRONMENT
- EFFECTS OF AGING
- FIGURE 4 FEMALE LIKELIHOOD OF GETTING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2008 (%)
- CONTRACEPTIVE INSURANCE COVERAGE
- TABLE 4 INSURANCE COVERAGE OF CONTRACEPTIVES BY STATE
- CONTRACEPTIVE USE IN TEENS INCREASES
- NEW USE FOR CONTRACEPTIVES
- AGING AND INFERTILITY
- CONTRACEPTIVE PATCH LINKED TO DEATHS
- WOMEN AND SEXUAL HEALTH
- INCIDENCE OF SEXUAL DYSFUNCTION
- VASCULAR TREATMENTS AND SEXUAL DYSFUNCTION
- DIAGNOSTICS
- NEW DEVELOPMENTS IN SEXUAL DYSFUNCTION TREATMENTS FOR WOMEN
- Alista
- TABLE 5 U.S. SEXUAL DYSFUNCTION PRODUCTS FOR WOMEN IN DEVELOPMENT, 2008
- SEXUAL DYSFUNCTION IN CANCER
- INFERTILITY AND CANCER
- CHEMOTHERAPY
- RADIATION
- PREVENTION STRATEGIES
- MARKETING AND WOMEN
- COUNTERFEIT PHARMACEUTICALS
- GENERIC PARTICIPATION
- TABLE 6 U.S. PRESCRIPTION GENERIC DRUG APPROVALS FOR CONSTRACEPTION BY COMPANY AND APPROVAL DATE, 2003-2008
- INTERNATIONAL ISSUES
- CHAPTER FOUR: AUTOIMMUNE DISEASES
- U.S. MARKET OVERVIEW
- MARKET SIZE
- TABLE 7 U.S. MARKET FORECAST FOR AUTOIMMUNE DISEASES BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
- COMPETITIVE ANALYSIS
- TABLE 8 MANUFACTURERS OF AUTOIMMUNE DISEASE PRODUCTS, 2008
- TABLE 9 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)
- FIGURE 5 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 (%)
- MARKET BY DISEASE TYPE
- CHRONIC FATIGUE SYNDROME
- Incidence and Mortality
- Market Indicators
- FIBROMYALGIA
- Incidence
- Diagnostics
- Pain in 11 of 18 Tender Point Sites on Digital Palpation
- Market Indicators
- Current Market Participants
- MYASTHENIA GRAVIS
- Incidence and Mortality
- Diagnostics
- Market Indicators
- Current Market Participants
- SJOGREN’S SYNDROME
- Incidence and Mortality
- Diagnostics
- Market Indicators
- Current Market Participants
- SYSTEMIC LUPUS ERYTHEMATOSUS
- Incidence and Mortality
- Diagnostics
- Market Indicators
- IN DEVELOPMENT
- PRESTARA
- AMPLIGEN
- RIQUENT
- ALL U.S. PRODUCTS IN DEVELOPMENT
- TABLE 10 U.S. AUTOIMMUNE DISEASE PRODUCTS IN DEVELOPMENT, 2008
- CHAPTER FIVE: WOMEN’S CANCERS
- U.S. MARKET OVERVIEW
- MARKET SIZE
- TABLE 11 U.S. MARKET FORECAST FOR WOMEN’S CANCER BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
- COMPETITIVE ANALYSIS
- TABLE 12 MANUFACTURERS OF WOMEN’S CANCER PRODUCTS, 2008
- TABLE 13 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)
- FIGURE 6 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 (%)
- MARKET BY TYPE OF CANCER
- BREAST CANCER
- TABLE 14 TNM CLASSIFICATIONS OF BREAST CANCERS
- TABLE 15 5-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2008 (%)
- Incidence and Mortality
- TABLE 16 TOTAL YEARLY CASES AND DEATHS FOR BREAST CANCER IN WOMEN WORLDWIDE, 2008
- Diagnostics
- Market Indicators
- Current Market Participants
- CERVICAL CANCER
- Incidence and Mortality
- Diagnostics
- Market Indicators
- Current Market Participants
- ENDOMETRIAL CANCER
- Incidence and Mortality
- Market Indicators
- Current Market Participants
- OVARIAN CANCER
- Incidence and Mortality
- Diagnostics
- Market Indicators
- Market Indicators (Continued)
- Current Market Participants
- IN DEVELOPMENT
- 572016
- ACTIMMUNE
- ARZOXIFENE
- ATAMESTANE
- FASLODEX
- IMC-C2259
- FABLYN
- OVAREX
- TEMSIROLIMUS
- THERATOPE
- OPAXIO
- A FEW SELECT U.S. PRODUCTS IN DEVELOPMENT
- TABLE 17 SELECTED WOMEN’S CANCER PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
- CHAPTER SIX: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES
- U.S. MARKET OVERVIEW
- TABLE 18 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS
- MARKET SIZE
- TABLE 19 U.S. MARKET FORECAST FOR GYNECOLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
- COMPETITIVE ANALYSIS
- TABLE 20 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- FIGURE 7 SUMMARY OF U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUES, 2008 (%)
- TABLE 21 MANUFACTURERS OF GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS, 2008
- MARKET BY DISEASE TYPE
- BACTERIAL VAGINOSIS
- Incidence
- Market Indicators
- CANDIDIASIS
- Incidence
- Market Indicators
- Current Market Participants
- CERVICAL DYSPLASIA
- Incidence
- CHLAMYDIA
- Incidence
- Diagnostics
- Market Indicators
- CONDYLOMA
- Incidence
- Market Indicators
- DYSMENORRHEA
- Incidence
- ENDOMETRIOSIS
- Incidence
- Market Indicators
- FIBROIDS
- Incidence
- Market Indicators
- GENITAL HERPES
- Incidence
- Diagnostics
- Market Indicators
- Current Market Participants
- PELVIC INFLAMMATORY DISEASE
- Incidence
- Market Indicators
- IN DEVELOPMENT
- HUMAN PAPILLOMAVIRUS
- LOW DOSE ORAL INTERFERON-ALPHA
- ALL U.S. PRODUCTS IN DEVELOPMENT
- TABLE 22 GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
- CHAPTER SEVEN: KIDNEY AND UROLOGIC DISEASES AND CONDITIONS
- U.S. MARKET OVERVIEW
- MARKET SIZE
- TABLE 23 U.S. MARKET FORECAST FOR KIDNEY AND UROLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
- COMPETITIVE ANALYSIS
- TABLE 24 U.S. KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- FIGURE 8 SUMMARY OF KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUES, 2008 (%)
- TABLE 25 MANUFACTURERS OF KIDNEY AND UROLOGIC DISEASE AND CONDITION PRODUCTS, 2008
- MARKET BY DISEASE TYPE
- URINARY TRACT INFECTIONS
- Incidence
- Diagnostics
- Market Indicators
- URINARY INCONTINENCE
- Incidence
- Market Indicators
- Current Market Participants
- TABLE 26 U.S. URINARY INCONTINENCE/OVERACTIVE BLADDER MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- URINARY INTERSTITIAL CYSTITIS
- Incidence
- Market Size and Growth
- IN DEVELOPMENT
- ALL U.S. PRODUCTS IN DEVELOPMENT
- TABLE 27 KIDNEY AND UROLOGICAL DISEASE AND CONDITIONS PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
- CHAPTER EIGHT: REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS
- U.S. MARKET OVERVIEW
- MARKET SIZE
- TABLE 28 U.S. MARKET FORECAST FOR REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
- COMPETITIVE ANALYSIS
- TABLE 29 U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- FIGURE 9 SUMMARY OF U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUES, 2008 (%)
- MARKET BY TYPE
- CONTRACEPTION
- TABLE 30 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)
- FIGURE 10 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)
- Market Indicators
- Most Commonly Used Oral Contraceptives
- TABLE 31 MOST COMMONLY USED ORAL CONTRACEPTIVES IN THE U.S., 2008 D)
- Current Market Participants
- TABLE 32 U.S. CONTRACEPTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- INFERTILITY
- Incidence
- Market Indicators
- Hormonal Therapy
- Surgical Treatment
- Artificial Insemination
- Assisted Reproductive Technology
- Current Market Participants
- TABLE 33 U.S. INFERTILITY MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- MENOPAUSE
- Incidence
- Market Indicators
- Most Commonly Used Menopause Treatment Products
- TABLE 34 MOST COMMONLY USED MENOPAUSE TREATMENT PRODUCTS 2008
- Current Market Participants
- TABLE 35 U.S. MENOPAUSE MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- IN DEVELOPMENT
- BAZEDOXIFENE/CONJUGATED ESTROGENS
- ALL U.S. PRODUCTS IN DEVELOPMENT
- TABLE 36 REPRODUCTIVE-RELATED PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
- CHAPTER NINE: RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
- U.S. MARKET OVERVIEW
- MARKET SIZE
- TABLE 37 U.S. MARKET FORECAST FOR RHEUMATOID ARTHRITIS AND OSTEOPOROSIS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
- COMPETITIVE ANALYSIS
- TABLE 38 U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- FIGURE 11 SUMMARY OF U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUES, 2008 (%)
- TABLE 39 MANUFACTURERS OF RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS, 2008
- MARKET BY TYPE
- RHEUMATOID ARTHRITIS
- Incidence
- Market Indicators
- Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs
- Cox-2 Inhibitors
- Disease-Modifying Anti-Rheumatic Drugs
- Immunosuppressants
- Corticosteroids
- Tumor Necrosis Factor Blocker
- B-lymphocyte-Restricted Differentiation Antigen (CD20) Inhibitor
- Selective Costimulation Modulator
- Current Market Participants
- TABLE 40 U.S. RHEUMATOID ARTHRITIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- OSTEOPOROSIS
- Incidence
- Diagnostics
- Market Indicators
- Current Market Participants
- TABLE 41 U.S. OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
- IN DEVELOPMENT
- PREXIGE
- REMICADE
- PREOS
- ARZOXIFENE
- FABLYN
- U.S. PRODUCTS IN DEVELOPMENT
- TABLE 42 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS IN DEVELOPMENT IN U.S., 2008
- CHAPTER TEN: MARKET SUMMARY
- U.S. WOMEN’S HEALTHCARE MARKET ANALYSIS
- TABLE 43 U.S. WOMEN’S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)
- FIGURE 12 U.S. WOMEN’S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)
- CHAPTER ELEVEN: INDUSTRY PARTICIPANTS BY TYPE
- TABLE 44 MAJOR WOMEN’S HEALTHCARE INDUSTRY PARTICIPANTS, BY PRODUCT TYPE, 2008
- SELECTED COMPANY PROFILES
- ASTRAZENECA
- BARR LABORATORIES, INC.
- BRISTOL-MYERS SQUIBB CO.
- ELI LILLY & CO.
- GENENTECH
- GLAXOSMITHKLINE
- MERCK & CO., INC.
- ORTHO-MCNEIL PHARMACEUTICALS
- PFIZER
- SERONO INTERNATIONAL S.A.
- WYETH
- LIST OF COMPANIES
Share this report
Other tasks Related Markets Obstetrics/Gynecology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
